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Introduction
Th  e role of vitamin D in relation to breast cancer 
incidence and outcome is controversial. Evidence from in 
vitro studies [1,2], animal studies [3,4], and selected 
clinical observational studies [5,6] has generally sup-
ported an association between higher vitamin D intakes 
and levels with lower breast cancer risk, but the results 
have not been consistent. Nonetheless, intervention 
strategies based on monitoring of vitamin D status with 
25-hydroxyvitamin D (25(OH)D) levels and supplemen-
tation with vitamin D have been proposed for implemen-
tation in breast cancer clinical practice [6-8].
In contrast are ﬁ  ndings from the 2011 report on dietary 
requirements for calcium and vitamin D from the 
Institute of Medicine (IOM) [9,10]. For cancer outcomes, 
the report concluded that ‘the evidence was inconsistent, 
inconclusive as to causality, and insuﬃ   cient to inform 
nutritional requirements’ [10]. Against this background, 
current evidence regarding vitamin D and breast cancer 
was reviewed to inform clinical practice and identify 
potential research directions.
Identifi  cation of studies
A literature search identiﬁ  ed observational studies and 
randomized clinical trials assessing associations among 
vitamin D intake and/or serum 25(OH)D levels and 
breast cancer incidence and outcome. We searched the 
PubMed and EMBASE databases and the American 
Society of Clinical Oncology and the San Antonio Breast 
Cancer Symposium proceedings through 31 January 
2011 for relevant reports. Search terms included vitamin 
D, 25-hydroxyvitamin D, 1,25-hydroxyvitamin D, and 
clinical breast cancer incidence and outcome. Th  e  same 
source literature was searched for review articles address-
ing optimal and recommended vitamin D intake and 
25(OH)D levels and determinants of 25(OH)D levels. 
Cross-referencing was used to complement relevant 
report identiﬁ  cation. Titles and abstracts were reviewed 
for relevance. Th   e full text was reviewed for those articles 
with relevant relationships.
Vitamin D intake and breast cancer incidence
Vitamin D intake (from diet and supplements) and breast 
cancer incidence have been examined in 10 case–control 
studies [11-20] and in 10 studies in cohorts with mixed 
results [5,21-29].
A meta-analyses of ﬁ  ve case–control studies reported 
no overall association between vitamin D intake and 
breast cancer risk (relative risk = 0.95, 95% conﬁ  dence 
interval (CI) = 0.69 to 1.32), but an analysis limited to 
premenopausal/perimenopausal women demonstrated a 
signiﬁ  cant association (relative risk = 0.83, 95% CI = 0.73 
to 0.95) [30]. Other case–control studies identiﬁ  ed signi-
ﬁ    cant associations in subgroups. In one study, vitamin D 
exposure mainly early in life (ages 10 to 19, based on 
outdoor activities) was strongly related to subsequent 
breast cancer risk (low to high quartile, odds ratio = 0.65, 
95% CI = 0.50 to 0.85) [17]. Similar to the studies by 
Abbas and colleagues [14] and Lin and colleagues [24], 
two recent studies found signiﬁ  cant associations between 
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premenopausal women [18,19].
While a signiﬁ  cant inverse association between vitamin 
D intake and breast cancer risk was seen in a meta-
analysis of six of the cohort studies (relative risk = 0.90, 
95% CI = 0.83 to 0.98) [30], this analysis did not include 
two recent, large, well-conducted, completely negative 
Scandinavian reports or the negative report from a large 
European cohort [26-28]. In the recent French E3N 
cohort report, only in regions with the highest ultraviolet 
solar radiance was high vitamin D intake associated with 
lower breast cancer risk (hazard ratio (HR) = 0.68, 95% 
CI = 0.54 to 0.85) [29].
25-Hydroxyvitamin D concentration and breast 
cancer incidence
Concentration of 25(OH)D is a generally accepted 
biomarker for determining vitamin D status [31], and 
studies of 25(OH)D and breast cancer incidence also 
provide mixed results. Four case–control studies signiﬁ  -
cantly associated lower 25(OH)D levels with higher 
breast cancer incidence [32-36]. In these studies, how-
ever, the 25(OH)D levels were obtained at some interval 
following breast cancer diagnoses with potential altera-
tions by cancer therapy or its sequellae. For example, 
women with lower physical activity have lower 25(OH)D 
levels, and physical activity is consistently decreased for 
years following a breast cancer diagnosis [37,38]. Positive 
associations may therefore not be reliable as only one 
case–control study adjusted for physical activity [33].
Six prospective nested case–control studies, which 
should provide more reliable ﬁ   ndings, have examined 
25(OH)D levels and subsequent breast cancer incidence 
[39-45]. In contrast to case–control studies, only one of 
these cohort studies that measure 25(OH)D before diag-
nosis reported a signiﬁ  cant association between 25(OH)
D levels and breast cancer incidence (Table 1) [45], while 
one study showed a borderline association [39]. In the 
positive French E3N cohort, the odds ratio was 0.73 (95% 
CI = 0.55 to 0.96, Ptrend = 0.02) and the association was 
stronger in younger women (age <53 years) [45]. Finally, 
in a rela  tively small cohort of female participants in the 
Th  ird National and Nutritional Examination Survey, no 
asso  cia  tion was seen between 25(OH)D levels and breast 
cancer mortality [46].
Th   e importance of incorporating physical activity as a 
covariate is illustrated in ﬁ  ndings from the prospective 
case–control study nested in the Women’s Health 
Initiative (WHI) cohort [42]. In analyses without body 
mass index and physical activity measures, a statistically 
signiﬁ  cant association was seen between lower 25(OH)D 
levels and higher breast cancer incidence. Th  e ﬁ  nding 
was attenuated, however, and became nonsigniﬁ  cant with 
inclusion of these factors in the analytic model [42].
25-Hydroxyvitamin D concentration in breast 
cancer patients
Several uncontrolled studies have reported a high 
frequency of low 25(OH)D levels in breast cancer 
patients [7,8,47,48]. In one study that identiﬁ  ed 74% of 
breast cancer patients deﬁ  cient for 25(OH)D (deﬁ  ned as 
<20 ng/ml or <50 nmol/l), despite a recommendation to 
take 400 IU vitamin D with calcium daily, few patients 
(<15%) achieved 25(OH)D levels >30 ng/ml (75 nmol/l) 
[47]. In a retrospective study of 500 newly diagnosed 
breast cancer patients, 69% were deﬁ  cient for 25(OH)D 
(deﬁ  ned as <32 ng/ml or <80 nmol/l) and were supple-
mented with 8,000 IU vitamin D3 daily (from 4,200 IU D3 
capsules). Th   e subsequent 25(OH)D values were increased 
(19.7 (8.0)  ng/ml vs. 37.6 (16.8)  ng/ml, respectively; 
P <0.01) but many remained <32 ng/ml [49].
Based on such ﬁ  ndings, some studies have suggested 
routine monitoring of 25(OH)D and supplemental vitamin 
D use for those identiﬁ  ed at low levels [7,47]. Others note 
that these uncontrolled observational study reports have 
not linked 25(OH)D to breast cancer outcomes [50,51]. 
In addition, the recent IOM report now recommends a 
lower 25(OH)D level than those used in several of these 
reports as being suﬃ     cient (>20 ng/ml or >50 nmol/l) 
[9,10].
25-Hydroxyvitamin D levels and breast cancer 
recurrence
Th  ree studies have examined the association between 
25(OH)D levels at diagnosis and subsequent breast 
cancer outcome (Table  2). Goodwin and colleagues 
followed a cohort of 522 early-stage breast cancer patients 
for a mean of 11.6 years [51]. Women were sampled post-
operatively before initiation of systemic adjuvant therapy. 
Th   ose women with deﬁ  cient 25(OH)D levels (deﬁ  ned as 
<50 nmol/l or <20 ng/ml), compared with those women 
with suﬃ   cient levels (>72 nmol/l), had a higher risk of 
distant recurrence (HR = 1.94, 95% CI = 1.16 to 3.25, 
P <0.01) and of death (HR = 1.73, 95% CI = 1.05 to 2.86, 
P <0.01). Th   e associations were attenuated, however, and 
became non  signiﬁ  cant after multivariate analysis adjust-
ing for traditional prognostic factors [51].
Piura and colleagues examined the same association in 
607 postmenopausal women with early-stage, hormone-
receptor-positive breast cancer participating in a 
randomized, controlled adjuvant trial in which all 
patients received tamoxifen with or without octreotide 
[52]. In this setting, no association between baseline 
25(OH)D levels and relapse-free survival or relapse at any 
site was seen [52].
Finally, a nested case–control analysis was conducted 
in the 3,085 early-stage, resected breast cancer patients 
participating in the Women’s Healthy Eating and Living 
study [53]. Women in this study evaluating a dietary 
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stage breast cancer diagnosis and were recurrence free at 
entry. In 512 matched pairs of breast cancer patients who 
had experienced cancer recurrence and control subjects 
who were recurrence-free at a comparable follow-up 
period, no association between 25(OH)D levels at base-
line and subsequent breast cancer recurrence was 
observed. Taken together, these three studies provide 
mixed ﬁ   ndings and no compelling evidence of an 
association between lower 25(OH)D levels and adverse 
breast cancer clinical outcome.
Th  e feasibility of conducting a randomized trial of 
vitamin D supplementation in adjuvant breast cancer has 
been explored recently. In women with early-stage, 
resected breast cancer, more than 80% were found to be 
already using vitamin D supplements at a median daily 
dose >1,200 IU/day and the median 25(OH)D levels were 
above 34.3% ng/ml (85.5 nmol/l), exceeding the suﬃ   cient 
level (20 ng/ml or 50 nmol/l). Considering such ﬁ  ndings, 
a phase III trial was not judged to be feasible [54].
Vitamin D and arthralgias in breast cancer patients
Low 25(OH)D levels have been associated with musculo-
skeletal disorders [55]. More recently, Chlebowski and 
colleagues found signiﬁ   cantly higher joint pain with 
extremely low 25(OH)D levels (<29 nmol/l or 12 ng/ml) 
Table 1. 25-Hydroxyvitamin D and breast cancer incidence: nested case–control studies in cohorts
     Case  Control
Cohort  Lead author  Cohort (n) patients  (n) subjects  (n)  Ptrend
a
Cancer Prevention Study II Nutrition Cohort  McCullough  21,965 516  516  0.60
Malmo Diet and Cancer Study  Almquist   53,000 764  764  NS
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial  Freedman  38,660 1,005  1,005  0.81
Women’s Health Initiative  Chlebowski   32,826 895  898  0.20
Nurses’ Health Study  Bertone-Johnson  32,826 701  724  0.06
French E3N Cohort  Engel  17,391  636  1,272  0.02b
aPtrend for analyses comparing breast cancer incidence in low versus high 25-hydroxyvitamin D groups. bFindings driven by results in women <53 years old at sampling.
Table 2. 25-Hydroxyvitamin D concentration and subsequent breast cancer outcome in patients with resected 
early-stage disease
Adjuvant therapy
Lead author n Category Hormonal therapy Chemotherapy
Mean follow-
up (years) Study outcome
Goodwin 512 Early breast cancer, 
resected
Tamoxifen per 
clinical decision
Varies per clinical 
decision
11.6 Defi  cient (<50 nmol/l) vs. suffi   cient 
(>72 nmol/l) 25(OH)D levels, in multivariant 
adjusted analysesa
Cohort Distant recurrence HR = 1.71 95% CI = 1.02 
to 2.86a
Premenopausal and 
postmenopausal
Survival HR = 1.60, 95% CI = 0.96 to 2.64
Piura 622 Early breast cancer, 
resected
Tamoxifen 
for 5 years vs. 
tamoxifen for 
5 years + octreotide 
for 2 years (per 
protocol)
Varies per clinical 
decision
7.9 No signifi  cant association with event-free 
survival or relapse-free survival with 25(OH)D 
level
Cohort within a 
randomized clinical trial
Postmenopausal
Jacobs 1,024 Early breast cancer, 
resected entered within 
4 years from diagnosis 
Varies per clinical 
decision
Varies per clinical 
decision
7.3 No signifi  cant association with breast cancer 
recurrence (local, regional, or distant) or death 
with 25(OH)D level
Nested case–control 
within a randomized 
clinical trial
Premenopausal and 
postmenopausal
CI, confi  dence interval; HR, hazard ratio; 25(OH)D, 25-hydroxyvitamin D. aFindings were statistically signifi  cant in analyses adjusted for age and tumor stage.
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breast cancer patients, aromatase inhibitors are not 
uncommonly associated with limiting arthralgias [57], 
which have been described as greater in those with low 
25(OH)D levels [58,59]. Currently, several prospective 
but nonrandomized trials evaluating higher dose vitamin 
D regimens have reported less joint pain in women who 
achieved relatively higher target 25(OH)D levels of 
40 ng/ml (100 nmol/l) [59] and 66 ng/ml (218 nmol/l on 
vitamin D supplementation) [60]. As the recent IOM 
report has identiﬁ  ed concerns about higher clinical risks 
at 25(OH)D levels >50 ng/ml (125 nmol/l) [9,10] and 
observations in a breast cancer cohort suggest survival 
may be optimal for women with 25(OH)D levels 
<44 ng/ml (110 nmol/l) [51], such high-dose vitamin D 
strategies require careful clinical trial evaluation before 
implementation in general practice.
Vitamin D, 25-hydroxyvitamin D levels and 
mammogram breast density
Reports of associations among vitamin D intake, 25(OH)
D levels and mammographic breast density have been 
mixed. Early reports associated higher vitamin D intake 
with lower mammographic breast density [61], perhaps 
especially in premenopausal women [62,63]. A series of 
more recent studies, however, reports no such association 
in either premenopausal women [64,65] or postmeno-
pausal women [64-68].
Randomized trials of calcium and vitamin D 
supplementation and breast cancer incidence
Th   e WHI randomized 36,282 postmenopausal women to 
placebo or supplementation with calcium (1,000 mg/day) 
plus vitamin D3 (400 IU/day), with hip fracture as the 
primary outcome and colorectal cancer and breast cancer 
as secondary outcomes [69,70]. After 7 years of inter  ven-
tion, there was no diﬀ  erence in invasive breast cancer 
incidence (528 vs. 546 breast cancers, respectively; HR = 
0.96, 95% CI = 0.85 to 1.09) between the randomi  zation 
groups. In sub  group analyses, women in the highest 
vitamin D intake quintile at entry (≥600 IU/day) actually 
had a higher breast cancer incidence with supplemental 
vitamin D use (HR = 1.34, 95% CI = 1.01 to 1.78) [42]. In 
the case–control analyses nested in this trial, the mean 
25(OH)D level was 50 ± 21 nmol/l among the 895 partici-
pants who subsequently were diagnosed with breast 
cancer, with a closely comparable level of 52 ± 21 nmol/l 
in the 898 matched controls who did not develop breast 
cancer [42].
One other clinical trial has evaluated calcium plus 
vitamin D inﬂ  uence on cancer risk in a smaller study 
using a larger vitamin D dose. In 1,179 postmenopausal 
women randomized to placebo, to calcium alone (1,400 
to 1,500 mg/day) or to calcium plus 1,100 IU vitamin D3/
day in a 1:2:2 ratio [71], there were fewer total cancers in 
the calcium plus vitamin D supplement compared with 
the placebo group (2.9% vs. 6.9%, P <0.05). Th  is  ﬁ  nding 
was based on the distribution of a total of 33 cancer cases 
but, as only 13 breast cancers were diagnosed, meaningful 
interpretation regarding breast cancer inﬂ  uence  is 
precluded.
Randomized clinical trials of vitamin D and total 
mortality in general populations
Vitamin D supplementation has been evaluated in a 
number of full-scale randomized, clinical trials, with or 
without calcium, mostly with fracture as the major 
endpoint. Th   ese trials have generally reported few details 
of clinical outcomes other than fractures or provided 
systematic evaluation of causes of death. Interest in the 
potential beneﬁ   t of vitamin D supplementation on a 
range of clinical outcomes and overall health, however, 
prompted interest in examining mortality in these 
randomized trials.
A meta-analysis of nine larger trials (all entering >582 
participants) incorporating 57,311 participants (includ-
ing 36,282 from the WHI trial [72]) identiﬁ  ed  4,777 
deaths during a median 5.7 years of follow-up [73]. Th  e 
trial size-adjusted mean vitamin D3 dose was a relatively 
modest 528 IU/day. Total mortality was 8% lower in the 
vitamin D supplement group, a ﬁ   nding of borderline 
signiﬁ  cance (HR = 0.92, 95% CI = 0.86 to 0.99, P <0.05) 
(Figure 1) [73]. A subsequent analysis suggested lower 
mortality when vitamin D was given with calcium 
supplementation [74]. Th   ese results should not be simply 
extrapolated to a ‘more is better’ concept since an 
observational study has suggested a U-shaped curve with 
lowest mortality risk at moderate 25(OH)D levels and 
increased mortality risk at both low and high levels of 
25(OH)D [75].
Further attempts to clarify this potential survival inﬂ  u-
ence of supplemental vitamin D in a conventional dose 
should be pursued with additional follow-up of existing 
conventional dose trials. In addition, there is an ongoing 
full-scale randomized trial evaluating supplemental 
vitamin D in a higher daily dose (2,000 IU D3) plus omega 
3 fatty acids (1,000 mg/day) versus placebo in a large 
population of about 20,000 otherwise healthy men and 
women [76]. Th  is trial has begun but results are not 
expected for several years. Additionally, the Vitamin D 
and Longevity trial is examining an intermittent high-
dose vitamin D regimen in the United Kingdom [77].
Supplemental vitamin D adverse eff  ects
While vitamin D is relatively safe, a review of randomized 
or quasi-randomized trials found adverse eﬀ  ects of hyper-
calcemia, gastrointestinal symptoms and renal disease 
signiﬁ   cantly increased by vitamin D adminis  tration in 
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of importance given the prevalence of renal deﬁ  ciency in 
breast cancer patients [78]. While several pilot studies of 
short-term, parental high-dose vitamin D on safety have 
been reported [60,79], the side eﬀ   orts of high-dose 
regimens for long duration use are unknown. Finally, the 
IOM report has identiﬁ   ed safety concerns potentially 
associated with 25(OH)D levels >50 ng/ml (>125 nmol/l) 
[9,10].
Factors infl  uencing 25-hydroxyvitamin D levels, 
vitamin D and breast cancer
It is not commonly recognized that factors other than 
sunlight exposure and vitamin D intake (both dietary and 
supplement) make a substantial contribution to 25(OH)D 
levels. In a pooling cohort consortium with 4,723 samples 
from 10 cohorts, statistically signiﬁ  cant positive corre-
lates of 25(OH)D included male sex, summer sample, 
physical activity and multivitamin use. Signiﬁ  cant nega-
tive correlates were body mass index, winter and spring 
samples, diabetes, sedentary behavior, smoking and Black 
race/ethnicity [80]. Th  e  ﬁ   ndings of relatively low 
25(OH)D levels in Black women compared with White 
women have led to speculation regarding the potential 
role of low 25(OH)D contributing to the observed ethnic 
disparity in breast cancer outcome [81,82].
In randomized trials, an inconsistent relation has been 
observed between total vitamin D intake (diet plus 
supplement) and subsequent 25(OH)D levels [83]. In the 
WHI cohort, when 25(OH)D levels were compared with 
total vitamin D intake (dietary and supplement) [42], the 
diﬀ  erence in median vitamin D intake comparing low 
(deﬁ   cient, 24  nmol/l) with high (optimal, 82 nmol/l) 
quintiles was only 238 IU daily, about one-half of the 
usual multivitamin tablet. In addition, only 3% of those in 
the highest quintile had vitamin D intakes >1,000 IU/day 
(Figure 2). Compared with vitamin D intake, stronger 
associations with 25(OH)D were seen for body mass 
index and physical activity with leaner, more physically 
active women having signiﬁ   cantly higher levels 
(P <0.0001) [42]. Failure to control for these two factors 
could thus potentially confound observational studies of 
25(OH)D and breast cancer.
In the WHI cohort, a multivariant predictive model 
could account for only 21% of the diﬀ  erences in 25(OH)D 
levels between individuals in a random sample of 3,055 
postmenopausal women [84]. Th  is ﬁ  nding is consistent 
with other reports in which a substantial proportion of 
25(OH)D diﬀ   erence between individuals is probably 
geneti  cally determined [85,86]. Th  e largely unexplained 
factors inﬂ  u  encing diﬀ  erences in 25(OH)D levels between 
individuals complicate understanding of associations with 
Figure 1. Vitamin D and total mortality in a meta-analysis of randomized controlled trials. Meta-analysis of randomized, controlled trials 
evaluating supplementation with vitamin D alone or in combination with calcium compared with placebo or no intervention on total mortality. 
The size of the box indicates the number of deaths, and the horizontal lines indicate the 95% confi  dence interval (CI). Adapted with permission 
from Autier and Gandini [73]. RR, relative risk.
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strategies.
Conclusions
Th  e recent IOM report on calcium and vitamin D 
require  ments provides an authoritative base for con-
sidera  tion of vitamin D and breast cancer issues. For 
vitamin D, the IOM recommendations are based primarily 
on bone health outcomes. Th   e total recommended daily 
vitamin D intake for women <71 years old is 600 IU/day. 
For those 71 years or older, an intake of 800 IU/day – 
corresponding to a serum 25(OH)D level of 20 ng/ml 
(50 nmol/l) – is recommended. Th  ese levels and cutoﬀ   
points are lower than proposed by some in the current 
literature but the IOM committee did not judge higher 
level recommen  dations to be justiﬁ  ed by available evi-
dence [9,10].Randomized clinical trial evidence indicates 
that vitamin D supplementation (at a dose of about 400 
to 800 IU/day), together with supplemental calcium, 
results in a modest decrease in fracture risk for women at 
higher fracture risk [87]. As many breast cancer patients 
are at fracture risk based on age and eﬀ  ects of cancer 
therapy (such as oophorectomy, chemotherapy-asso  ciated 
amenor  rhea, and aromatase inhibitors), use of vitamin D 
supplements (400 to 800 IU/day) plus calcium in those at 
increased fracture risk can be recommended. For early-
stage breast cancer patients, suggestions regard  ing routine 
monitoring of 25(OH)D levels and vitamin D supple-
mentation to some target level are inferential and based on 
mixed observational study results.
Current evidence is suﬃ   cient to support further study 
of factors inﬂ   uencing 25(OH)D levels, associations 
between 25(OH)D levels and breast cancer in premeno-
pausal and Black women, moderate dose (≤2,000 IU D3/
day) supplemental vitamin D use and breast cancer 
incidence, and observational studies evaluating whether a 
threshold higher 25(OH)D level is associated with 
adverse clinical outcome in women with breast cancer. 
Before routine clinical application of any strategies 
target  ing vitamin D status for breast cancer prevention or 
therapy are undertaken, the limitations of the current 
evidence should be considered.
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Figure 2. Total vitamin D intake and serum 25-hydroxyvitamin D by quintile. Individual total vitamin D intake (diet plus supplementation) 
and serum 25-hydroxyvitamin D (25(OH)D) levels at baseline. Serum 25(OH)D levels from 1,067 women identifi  ed as control subjects from a nested 
case–control study performed in the Women’s Health Initiative trial evaluating calcium and vitamin D. Daily intakes of dietary and supplemental 
vitamin D were determined from self-report. The range of vitamin D intakes substantially overlaps in each 25(OH)D quintile. Line segments connect 
the mean vitamin D intake level in each quintile, which was 23.6, 38.5, 49.2, 60.9, and 81.9 nmol/l, respectively. Adapted with permission from 
Chlebowski and colleagues [42].
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